PPMI driven sample size estimation for clinical trials in Parkinson’s disease
Objective: To utilize clinical, imaging and CSF data from the Parkinson’s Progression Markers Initiative (PPMI) to estimate the sample size for disease modification studies in…A Psychometric Analysis of the MDS UPDRS-II and III in Early Parkinson’s disease: Do the Numbers Add Up?
Objective: Our objective was to explore the psychometric evidence for the use of the Movement Disorder Society Unified Parkinson’s Disease Rating Scale (MDS-UPDRS) part II…The Small Molecule Alpha-Synuclein Misfolding Inhibitor, NPT200-11, Produces Multiple Benefits in an Animal Model of Parkinson’s Disease
Objective: To evaluate effects of NPT200-11 on Parkinson’s disease (PD)-relevant outcomes including alpha-synuclein pathology, neurodegenerative markers and motor performance in transgenic mouse models of PD.…A Study to Evaluate the Efficacy of PRX002/RG7935 in Participants With Early Parkinson’s Disease (PASADENA) – Study Design
Objective: To evaluate the efficacy of the anti-alpha-synuclein monoclonal antibody PRX002/RG7935 in a proof-of-concept Phase 2 study in patients with early Parkinson’s disease (PD). Background:…VY-AADC01 gene therapy in Parkinson’s disease: Interim results of the on-going Phase 1b PD-1101 trial
Objective: Evaluate the safety of VY-AADC01, an AAV2 gene therapy vector with human aromatic L-amino acid decarboxylase (AADC) administered bilaterally to the putamen using intraoperative…Clinical Relevance of Treatment With OnabotulinumtoxinA in Patients With Cervical Dystonia: Results From the CD Probe Study
Objective: To explore minimal clinically important change perceived by patients as beneficial by the Toronto Western Spasmodic Torticollis Rating Scale (TWSTRS) using data from the…Physical Activity in Early Parkinson Disease
Objective: To characterize physical activity habits in patients with early Parkinson disease (PD). Background: Physical activity is an important therapy for PD as it may…Preventing Levodopa Induced Dyskinesia with Docosohexanoid Acid in Parkinson Disease
Objective: The purpose of this study was to determine if Docosohexanoic acid (DHA) affects the speed and severity of development of levodopa induced dyskinesia (LID) in subjects starting levodopa (LD).…Virtual research visits in individuals with Parkinson disease enrolled in a clinical trial: REACT-PD Study Interim Analysis
Objective: To demonstrate the feasibility, reliability, and value of conducting web-based clinical trial assessments in individuals with Parkinson disease (PD). Background: Increasing interest has been…Multi-modal retention in a phase III clinical trial in early Parkinson disease (STEADY-PD III)
Objective: To evaluate novel retention strategies in an ongoing phase 3 clinical trial in individuals with Parkinson disease (PD) Background: Adequate participant retention is a…
- « Previous Page
- 1
- …
- 11
- 12
- 13
- 14
- 15
- 16
- Next Page »